PELL BIO-MED TECHNOLOGY CO. LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159 TWD | -3.05% |
|
-2.15% | 0.00% |
| 1 week | -2.15% | ||
| Current month | -4.22% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 17.16M 529K | Sales 2023 | 18.03M 556K | Capitalization | 8.85B 273M |
|---|---|---|---|---|---|
| Net income 2022 | -230M -7.1M | Net income 2023 | -399M -12.31M | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | - |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 57.39% |
More Fundamentals
* Assessed data
| 1 day | -3.05% | ||
| 1 week | -2.15% | ||
| Current month | -4.22% | ||
| 1 month | +58.21% |
1 week
159.00
177.50
1 month
114.50178.50
Current year
70.60178.50
1 year
70.60178.50
3 years
70.60178.50
5 years
70.60178.50
10 years
70.60178.50
Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 273M | |
| +23.37% | 47.02B | |
| +49.90% | 41.86B | |
| -0.94% | 41.76B | |
| -4.32% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- 6949 Stock